Triple-hormone drug retatrutide shows up to 30% weight loss in late-stage trial
In a phase-III study, Eli Lilly's retatrutide led participants to lose an average of 25% of body weight after 80 weeks, with further reductions after 104 weeks, while also improving several obesity-related health measures.
Eli Lilly reported that participants receiving the highest dose of its triple-hormone obesity medication retatrutide lost an average of 25% of their body weight after 80 weeks in a late-stage trial, with the average loss rising to about 30% after 104 weeks. More than one-third of those treated lost at least 30% of their weight.
In sub-analyses, the drug reduced knee pain by up to 62% in participants with obesity-related osteoarthritis and cut the frequency of sleep-apnea events by up to 57% in those with obstructive sleep apnea. Cardiometabolic markers, including blood pressure, triglycerides and LDL cholesterol, improved across the study population. Among participants who began the trial with prediabetes, over 90% no longer met the diagnostic criteria by the end of the study.
The multinational trial enrolled 2,339 adults with an average baseline weight of 113 kg and a mean BMI of 40. Participants were randomized to receive weekly injections of 4 mg, 9 mg, 12 mg of retatrutide, or a placebo. The results were published in the New England Journal of Medicine.
Retatrutide combines synthetic analogues of the hormones GLP-1, GIP and glucagon, aiming to enhance satiety, insulin regulation and lipid metabolism. The peptide remains active in the bloodstream for about six days, allowing for once-weekly dosing. Safety findings were similar to those of existing GLP-1-based therapies, with the most common adverse events being mild gastrointestinal symptoms. Ten cardiovascular events and ten cases of pancreatitis were reported, half of which occurred in the placebo group, but the trial size was insufficient to draw definitive conclusions about rare risks.
The study did not include a head-to-head comparison with other approved obesity treatments, such as tirzepatide, leaving the relative efficacy of retatrutide to be determined in future research.